Antipsychotic Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Antipsychotic stocks.

Antipsychotic Stocks Recent News

Date Stock Title
Jul 3 JNJ Johnson & Johnson: A Lot Of Moving Parts, But Perhaps Finally Lurching In The Right Direction
Jul 3 JNJ Johnson & Johnson: Put Selling Can Yield A Potential 9.8% Return
Jul 3 JNJ How Small Biotech Halozyme, With A 41% Run, Is Getting Under Your Skin
Jul 3 JNJ Health Canada Authorizes RYBREVANT® (amivantamab) in Combination with Carboplatin and Pemetrexed as the Only Targeted First-line Treatment Approved for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Jul 3 JNJ Johnson & Johnson gains FDA and EC approvals for TB treatment
Jul 3 JNJ Johnson & Johnson reports data from Phase III multiple myeloma treatment trial
Jul 2 JNJ Johnson & Johnson's Cell Therapy Carvykti Shows Better Survival Rate In Pretreated Blood Cancer Patients
Jul 2 JNJ Court Rules Against Johnson & Johnson In Talcum Powder Cancer Study Case
Jul 2 JNJ J&J says Carvykti beat standard drugs in late-stage blood cancer trial
Jul 2 JNJ CARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
Jul 1 JNJ 5 Biggest Winners, 5 Biggest Losers From Dow Jones Industrial Average In First Half 2024
Jul 1 JNJ J&J looks to challenge argenx’s Vyvgart with positive Phase III data
Jul 1 JNJ 3 Magnificent Stocks Retirees Can Buy and Hold Forever
Jul 1 JNJ Merck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
Jun 30 JNJ 2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
Jun 29 JNJ J&J talc claimants lose bid to block company's bankruptcy bid
Jun 29 JNJ 4 Cheap Stocks to Buy in July
Jun 28 JNJ How Medicare drug price negotiations could hit pharma stocks
Jun 28 JNJ J&J reports positive phase 3 data for nipocalimab for neuromuscular disease
Jun 28 JNJ Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients
Antipsychotic

Antipsychotics, also known as neuroleptics, are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia but also in a range of other psychotic disorders. They are also the mainstay together with mood stabilizers in the treatment of bipolar disorder.The use of antipsychotics may result in many unwanted side effects such as involuntary movement disorders, gynecomastia, impotence, weight gain and metabolic syndrome. Long-term use can produce adverse effects such as tardive dyskinesia.
First-generation antipsychotics, known as typical antipsychotics, were first introduced in the 1950s, and others were developed until the early 1970s. Second-generation drugs, known as atypical antipsychotics, were introduced firstly with clozapine in the early 1970s followed by others. Both generations of medication block receptors in the brain for dopamine, but atypicals tend to act on serotonin receptors as well. Neuroleptic, originating from Greek: νεῦρον (neuron) and λαμβάνω (take hold of)—thus meaning "which takes the nerve"—refers to both common neurological effects and side effects.

Browse All Tags